Detail Information of Xenobiotics
| General Information of Xenobiotics (ID: XEO00624) | ||||||
|---|---|---|---|---|---|---|
| Xenobiotics Name |
NCX-4016
|
|||||
| Xenobiotics Type |
Pharmaceutical Agent(s)
|
|||||
| Classification |
Drug in Phase 2 Clinical Trial
|
|||||
| Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=119032"></iframe>
|
 |
||||
| 3D MOL | 2D MOL | |||||
| PubChem CID | ||||||
| DME(s) Modulated by This Xenobiotics | ||||||
| DME(s) Induced by This Xenobiotics | ||||||
| Serum paraoxonase/arylesterase 1 (PON1) | DME Info | Homo sapiens | [1] | |||
| References | ||||||
| 1 | Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.